Pipeline Overview

Our expanding development program currently includes four repurposed drugs, in different phases of development.

Code Indication Drug Status Human Efficacy Patent Protection Regulatory Pathway
OP001 Opioid Addiction Reformulated generic Yes Pending 505(B)(2)
OP002 Pain Reduction Alternative in Opioid Users Reformulated generic Yes Pending 505(B)(2)
OP003 Prevention of Opioid Induced Respiratory Depression Reformulated generics combination Yes Pending 505(B)(2)
OP004 Enhanced Effect Lower Dose Opioids for Pain Relief Reformulated generics combination Yes Pending 505(B)(2)